Loading...
Vandetanib and indwelling pleural catheter for non-small cell lung cancer with recurrent malignant pleural effusion
BACKGROUND: Non-small-cell lung cancer patients with malignant pleural effusion have a poor overall median survival (4.3 months). Vascular endothelial growth factor (VEGF) is a key regulator of pleural effusion production. It is unknown if pharmacological inhibition of VEGF signaling modifies the di...
Na minha lista:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2014
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4160385/ https://ncbi.nlm.nih.gov/pubmed/24913066 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cllc.2014.04.002 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|